These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29335342)

  • 21. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis.
    Wang R; Dasgupta A; Ward MM
    JAMA Netw Open; 2022 Mar; 5(3):e222312. PubMed ID: 35289857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
    Fong W; Holroyd C; Davidson B; Armstrong R; Harvey N; Dennison E; Cooper C; Edwards CJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1837-42. PubMed ID: 27354684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.
    Kubo Y; Ohishi M; Nakashima Y; Okazaki K; Fukushi J; Oyamada A; Iwamoto Y
    Fukuoka Igaku Zasshi; 2015 Dec; 106(12):316-22. PubMed ID: 27159947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
    Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.
    Chou CT; Tsai CY; Liang TH; Chang TM; Lai CH; Wei CC; Chen KH; Lin SC; Yu CL; Liou LB; Luo SF; Lee CS; Hsue YT; Huang CM; Chen JH; Lai NS; Cheng HH; Cheng TT; Lai HM; Tsai WC; Yen JH; Lu LY; Chang CP
    Mod Rheumatol; 2010 Dec; 20(6):580-7. PubMed ID: 20683633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etanercept in the longterm treatment of patients with ankylosing spondylitis.
    Dijkmans B; Emery P; Hakala M; Leirisalo-Repo M; Mola EM; Paolozzi L; Salvarani C; Sanmarti R; Sibilia J; Sieper J; Van Den Bosch F; van der Heijde D; van der Linden S; Wajdula J
    J Rheumatol; 2009 Jun; 36(6):1256-64. PubMed ID: 19411393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
    Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
    Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
    Dong Y; Li P; Xu T; Bi L
    Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.